Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EPS (Basic): 2010-2024

Historic EPS (Basic) for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to -$1.34.

  • Altimmune's EPS (Basic) rose 34.38% to -$0.21 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.07, marking a year-over-year increase of 31.85%. This contributed to the annual value of -$1.34 for FY2024, which is 19.28% up from last year.
  • As of FY2024, Altimmune's EPS (Basic) stood at -$1.34, which was up 19.28% from -$1.66 recorded in FY2023.
  • Altimmune's 5-year EPS (Basic) high stood at -$1.34 for FY2024, and its period low was -$2.35 during FY2021.
  • For the 3-year period, Altimmune's EPS (Basic) averaged around -$1.60, with its median value being -$1.66 (2023).
  • Its EPS (Basic) has fluctuated over the past 5 years, first declined by 23.04% in 2021, then grew by 22.98% in 2022.
  • Altimmune's EPS (Basic) (Yearly) stood at -$1.91 in 2020, then dropped by 23.04% to -$2.35 in 2021, then rose by 22.98% to -$1.81 in 2022, then increased by 8.29% to -$1.66 in 2023, then grew by 19.28% to -$1.34 in 2024.